Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. [Phase 3]

View source ↗

Summary

An open-label extension study in adults (16 years and older) with partial-onset seizures evaluated the safety and tolerability of RWJ 333369 as an adjunctive th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complex Partial Seizures
• Epilepsy

Drugs mentioned

• RWJ 333369 (RWJ-333369)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Epilepsy, Complex Partial Seizures | Phase 3 | Status: COMPLETED